Moxifloxacin 1a Pharma (Moxifloxacin)

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections of the respiratory and skin systems.

• Community‑acquired bacterial pneumonia: Improves clinical cure rates and reduces bacterial load in adult patients.
• Acute bacterial sinusitis: Relieves sinus inflammation by eradicating the causative pathogens.
• Acute bacterial exacerbation of chronic bronchitis: Shortens duration of symptoms and prevents progression.
• Skin and skin structure infections: Achieves bacterial clearance in cellulitis, abscesses and wound infections.

• Moxifloxacin exerts its antibacterial activity by binding to the DNA gyrase (topoisomerase II) and topoisomerase IV enzymes of susceptible bacteria. This inhibition prevents the supercoiling and resealing of bacterial DNA during replication and transcription, leading to accumulation of double‑strand breaks and bacterial cell death. The dual targeting of both enzymes enhances potency against Gram‑positive, Gram‑negative and atypical respiratory pathogens in clinical infections.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea
• Diarrhea
• Headache
• Dizziness
• Abdominal pain
• Rash

Serious or Rare Side Effects

• Tendon rupture or tendonitis
• QT interval prolongation leading to arrhythmia
• Severe allergic reactions such as anaphylaxis
• Clostridioides difficile‑associated diarrhea
• Hepatic dysfunction
• Peripheral neuropathy

When prescribing Moxifloxacin, clinicians should consider several safety factors.

• Renal impairment: Adjust therapy based on renal function and monitor creatinine.
• History of tendon disorders: Avoid use in patients with prior tendon inflammation or recent fluoroquinolone exposure.
• Cardiac risk: Use cautiously in patients with known QT prolongation or electrolyte abnormalities.
• Concomitant CYP450 inhibitors: Review potential for increased plasma levels.
• Pregnancy and lactation: Use only if benefits outweigh risks; data are limited.
• Store at ambient temperature: Keep below 25 °C, in original packaging, protected from moisture and light.

Moxifloxacin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: Reduce absorption of moxifloxacin.
• Corticosteroids: Increased risk of tendon rupture.
• Warfarin: May potentiate anticoagulant effect, monitor INR.

Moderate Interactions (Monitor Closely)

• Non‑cardiac QT‑prolonging drugs: May have additive effect on QT interval.
• Theophylline: May increase plasma concentrations of theophylline.
• Cytochrome P450 inducers (e.g., rifampin): May lower moxifloxacin levels.